Earn 4.75 CME Credits

Click below to register.

SATURDAY, November 23rd, 2019

The Westin Buckhead Atlanta

3391 Peachtree Road NE
Atlanta, GA

Room: Woodruff Room – Lobby level

Registration and Breakfast 7:30 AM – 8:00 AM
Interactive CME Activity 8:00 AM – 1:00 PM

This activity is supported by an educational grant from Novo Nordisk Inc.

The progressive nature of type 2 diabetes (T2DM) often requires the evolution of pharmacotherapy to include the use of injectable therapies. Over the last few years, newer insulins and injectable glucagon-like peptide 1 receptor agonists (GLP-1 RAs) have the potential to significantly improve glycemic control without the limitations associated with older insulins. The recent approval of an oral GLP-1 RA offers an additional treatment option. Despite these advances, gaps remain with clinician skills to initiate these newer therapies. This dynamic live workshop will address these gaps by discussing the latest evidence-based clinical information on the effective use of newer injectable therapies for patients with T2DM. It will also offer hands-on opportunities to collaborate with peers in a workshop setting simulating actual patient care to develop individualized patient treatment plans and share best practices.

The goals of this activity are to provide the latest evidence on newer injectable therapies for the management of patients with T2DM and to offer an opportunity for clinicians to improve their skills in patient evaluation and therapeutic implementation of treatment programs, leveraging multidisciplinary treatment support, to utilize these newer pharmacotherapeutic options.

Primary care and endocrinology physicians, physician assistants, nurse practitioner, nurses, and other healthcare providers who participate in the management of patients with T2DM. No prerequisites required.

At the conclusion of this activity, participants will be able to:
  • DESCRIBE the pathophysiology and progression of T2DM as it relates to the eventual need for injectable therapies to manage blood glucose.
  • IDENTIFY provider and patient-derived barriers that contribute to clinical inertia regarding the initiation and intensification of injectable therapy in T2DM.
  • COMPARE the efficacy, safety, and clinical indications of basal and prandial insulin, injected and evolving oral GLP1-RAs, and GLP1-RA/insulin FRCs+ as part of T2DM treatment.
  • EXPLAIN appropriate injection technique considering available insulin, GLP-1 RA, and GLP1-RA/insulin delivery devices.
  • RECOGNIZE clinical scenarios in which progression to an injectable antidiabetes therapy may be appropriate.
  • DESIGN appropriate injectable antidiabetic treatment plans, including injected or oral medication selection, dosing/titration, and AE+ mitigation and management.
  • INCORPORATE shared decision-making strategies to facilitate the appropriate utilization of injectable therapies as part of overall T2DM management.

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Joslin Diabetes Center and ASiM CE LLC. Joslin Diabetes Center is accredited by the ACCME to provide continuing medical education for physicians.

Joslin Diabetes Center designates this live activity for a maximum of 4.75 AMA PRA Category 1 CreditsTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

7:30 – 8:00 AM Welcome and Introduction
8:00 – 8:10 AM Opening Remarks and Faculty Introductions
8:10 – 8:25 AM Pathophysiology and Progression of T2DM: The Indication for Injectable Therapy
8:25 – 9:00 AM Exploring Today’s Injectable Antidiabetes Therapies: Insulins
9:00 – 9:35 AM Injectable and Oral GLP-1 RAs and GLP-1 RA/Insulin Combinations
9:35 – 9:50 AM Facilitating Advancement to Injection Therapy in T2DM
9:50 – 10:15 AM Case Vignette Faculty Panel Discussion
10:15 – 10:35 AM Break
10:35 – 11:05 AM Faculty Panel Discussion: Practical Administration of Injectable Therapies
11:05 – 12:35 PM Case Simulation Small Group Activity: Utilizing Newer Therapies in a Clinical Practice
12:35 – 12:50 PM Question and Answer Session
12:50 – 1:00 PM Closing Remarks and Postassessment

This schedule is subject to change.

Richard S. Beaser, MD (Course Director)
Senior Staff Physician
Medical Director, Continuing Medical Education
Senior Strategic Advisor, Education Programs
Joslin Diabetes Center
Associate Professor of Medicine
Harvard Medical School
Boston, Massachusetts

Alissa R. Segal, PharmD, CDE, CDTC, FCCP
Professor of Pharmacy Practice
MCPHS University Clinical Pharmacist
Joslin Diabetes Center
Boston, Massachusetts

Bruce W. Bode, MD, FACE
Clinical Associate Professor of Medicine
Emory University School of Medicine
President and CEO
Atlanta Diabetes Associates
Atlanta, Georgia

Mark W. Stolar, MD
Associate Professor of Clinical Medicine
Feinberg School of Medicine
Northwestern University
Chicago, Illinois

Americans with Disabilities Act (ADA)
Joslin Diabetes Center and ASiM CE LLC fully comply with the legal requirements of the ADA and the rules and regulations thereof.

There is no fee for this educational activity.

Submit a case to review at meeting:

<img src="" alt="procced to pretest" border="0" />

MyCMESite is published by ASiM CE, LLC, d/b/a ASiM 166 W. Main Street, Somerville, NJ 08876. (908) 253-9001. Copyright ©2017 by ASiM CE, LLC. All rights reserved. No part of this publication may be reproduced or transmitted in any form or by any means, electronic or mechanical, without first obtaining permission from the publisher. ASiM is a registered trademark of ASiM CE LLC. Contact Us